The novel FAT4 activator jujuboside A suppresses NSCLC tumorigenesis by activating HIPPO signaling and inhibiting YAP nuclear translocation-Reference-Cited by-同舟云学术

The novel FAT4 activator jujuboside A suppresses NSCLC tumorigenesis by activating HIPPO signaling and inhibiting YAP nuclear translocation

Published:2021-08 Issue: Volume:170 Page:105723
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Wang Wensheng,Huang Qiuju,Chen Yao,Huang Zhiying,Huang Yanfang,Wang Ying,Qi Xiaoxiao,Liu Zhongqiu,Lu Linlin

Funder

Natural Science Foundation of Guangdong Province for Distinguished Young Scholars

National Natural Science Foundation of China

State Administration for Science, Technology and Industry for National Defense

Traditional Chinese Medicine Bureau of Guangdong Province

Guangdong Provincial Key Laboratory for Translational Cancer Research of Chinese Medicine, Guangzhou University of Chinese Medicine

Publisher

Elsevier BV

Subject

Pharmacology

Reference56 articles.

1. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA: a Cancer J. Clin.,2018

2. Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through wnt/beta-catenin signaling;Tong;Oncotarget,2016

3. Management of non-small cell lung cancer with egfr mutation: the role of radiotherapy in the era of tyrosine kinase inhibitor therapy-opportunities and challenges;Xia;J. Thorac. Dis.,2017

4. Osimertinib in untreated egfr-mutated advanced non-small-cell lung cancer;Soria;N. Engl. J. Med.,2018

5. Her2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-her receptor tyrosine kinase inhibitor pyrotinib;Wang;Ann. Oncol.,2019

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JuA alleviates liver ischemia-reperfusion injury by activating AKT/NRF2/HO-1 pathways;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-12

2. IL-32 aggravates metabolic disturbance in human nucleus pulposus cells by activating FAT4-mediated Hippo/YAP signaling;International Immunopharmacology;2024-11

3. Jujuboside A through YY1/CYP2E1 signaling alleviated type 2 diabetes-associated fatty liver disease by ameliorating hepatic lipid accumulation, inflammation, and oxidative stress;Chemico-Biological Interactions;2024-09

4. Chinese botanical drugs targeting mitophagy to alleviate diabetic kidney disease, a comprehensive review;Frontiers in Pharmacology;2024-05-13

5. Olive and Winter Jujube Seeds in Cancer Prevention and Treatment;Seeds: Anti-proliferative Storehouse for Bioactive Secondary Metabolites;2024